Screener
Regenxbio RGNX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(67,342) | $(64,788) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 17,670 | 17,190 |
| Depreciation and amortization | 7,614 | 7,860 |
| Net accretion of discounts on marketable debt securities | (1,321) | (2,427) |
| Net realized gain on investments | (16) | — |
| Non-cash interest expense | 9,740 | 2,490 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's stock-based comp?
- Regenxbio (RGNX) reported stock-based comp of $9.05M in Q2 2026.
- How has Regenxbio's stock-based comp changed year-over-year?
- Regenxbio's stock-based comp increased by 4.6% year-over-year, from $8.65M to $9.05M.
- What is the long-term trend for Regenxbio's stock-based comp?
- Over 4 years (2021 to 2025), Regenxbio's stock-based comp has grown at a -2.9% compound annual growth rate (CAGR), from $38.81M to $34.56M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Regenxbio's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude